-
公开(公告)号:US20240238258A1
公开(公告)日:2024-07-18
申请号:US18389887
申请日:2023-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: HAIBO LIU , YUCHENG MU , ANNAPURNA PENDRI , SHOSHANA L. POSY , JOANNE JEWETT BRONSON , LOUIS S. CHUPAK , LAURA AKULLIAN D'AGOSTINO
IPC: A61K31/433 , A61K39/395 , C07D417/12
CPC classification number: A61K31/433 , A61K39/3955 , C07D417/12
Abstract: Disclosed are compounds of Formula (I)
pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.-
公开(公告)号:US20240317718A1
公开(公告)日:2024-09-26
申请号:US18560485
申请日:2022-05-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: STEVEN H. SPERGEL , RYAN M. MOSLIN , MICHAEL EDWARD MERTZMAN , SHOSHANA L. POSY , SIRISH KAUSHIK LAKKARAJU , JOSEPH A. TINO , ZILI XIAO , CHUNJIAN LIU , JAMES LIN
IPC: C07D403/12 , A61K31/501 , A61K31/506 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12 , C07D417/14
CPC classification number: C07D403/12 , A61K31/501 , A61K31/506 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
公开(公告)号:US20240207238A1
公开(公告)日:2024-06-27
申请号:US18504196
申请日:2023-11-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: ANNAPURNA PENDRI , HAIBO LIU , SHOSHANA L. POSY , YUCHENG MU , JOANNE JEWETT BRONSON , LAURA AKULLIAN D'AGOSTINO
IPC: A61K31/4439 , A61K39/395 , A61P35/00 , C07D417/14
CPC classification number: A61K31/4439 , A61K39/3955 , A61P35/00 , C07D417/14
Abstract: Disclosed are compounds of Formula (I):
pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.-
公开(公告)号:US20240228476A1
公开(公告)日:2024-07-11
申请号:US18389891
申请日:2023-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: HAIBO LIU , YUCHENG MU , ANNAPURNA PENDRI , SHOSHANA L. POSY , JOANNE JEWETT BRONSON , LOUIS S. CHUPAK , LAURA AKULLIAN D'AGOSTINO
IPC: C07D417/12 , A61K45/06 , A61P35/00 , C07K16/28
CPC classification number: C07D417/12 , A61K45/06 , A61P35/00 , C07K16/2818 , C07K16/2827
Abstract: Disclosed are compounds of Formula (I)
pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.-
公开(公告)号:US20240180886A1
公开(公告)日:2024-06-06
申请号:US18504198
申请日:2023-11-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: YUCHENG MU , HAIBO LIU , ANNAPURNA PENDRI , SHOSHANA L. POSY , JOANNE JEWETT BRONSON , LAURA AKULLIAN D'AGOSTINO
IPC: A61K31/4439 , A61K31/5377 , A61K39/395 , A61P35/00 , C07D417/12
CPC classification number: A61K31/4439 , A61K31/5377 , A61K39/3955 , A61P35/00 , C07D417/12
Abstract: Disclosed are compounds of Formula (I)
pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.
-
-
-
-